OXBDF News and Press, Oxford BioMedica From 07/20/20

Results from a 508-subject Phase 1 clinical trial, just published online in The Lancet , showed that AstraZeneca's ( AZN -0.1% ) COVID-19 vaccine candidate showed a seroconversion rate at high as 97% at day 28. More news on: AstraZeneca PLC, Oxford Biomedica plc, Healthcare stocks ne...

Giddy investors are bidding up AstraZeneca ( AZN +6.5% ) on reports that it may release an update on COVID-19 vaccine candidate AZD1222 tomorrow. More news on: AstraZeneca PLC, IQVIA Holdings Inc., GlaxoSmithKline plc, Healthcare stocks news, Stocks on the move, Read more ...

Oxford Biomedica plc ( OTCPK:OXBDF +4.0% ) closes a five-year agreement with the non-profit Vaccines Manufacturing and Innovation Center (VMIC) aimed at scaling up production of AstraZeneca's ( AZN -2.4% ) AZD1222, its COVID-19 vaccine candidate. More news on: Oxford BioMedica p...

Oxford Biomedica ( OTCPK:OXBDF ) has signed a one year Clinical & Commercial Supply Agreement with AstraZeneca (NYSE: AZN ). More news on: Oxford BioMedica plc, AstraZeneca PLC, Healthcare stocks news, Read more ...

Oxford BioMedica ( OTCPK:OXBDF ): FY GAAP EPS of -22.10p. More news on: Oxford BioMedica plc, Earnings news and commentary, Tech stocks news, Read more ...

Axovant Gene Therapies ( AXGT ) is running three clinical programs on three gene therapy candidates for neurological and developmental disorders. Readouts from all three programs are expected in Q4'19, presenting an opportunity for a trade, which is the focus of this article. A big Q4'19 u...

Oxford BioMedica plc (OXBDF) Q2 2019 Earnings Conference Call September 4, 2019 8:00 A.M. ET Company Participants Catherine Isted - Head-Corporate Development and Investor Relations John Dawson - Chief Executive Officer Stuart Paynter - Chief Financial Officer Kyriacos Mitropha...

The following slide deck was published by Oxford BioMedica plc in conjunction with their 2019 Q2 earnings Read more ...

Oxford BioMedica ( OTCPK:OXBDF ): 1H GAAP EPS of -14.83p. More news on: Oxford BioMedica plc, Earnings news and commentary, Tech stocks news, Read more ...

In February I wrote about Axovant Gene Therapies Ltd ( AXGT ), formerly Axovant Sciences ( AXON-OLD ), providing my thoughts on data expected in March 2019 from two of the company's trials, one in Parkinson's disease and one in GM2 gangliosidosis. I believed it was too early to recommend a l...